ArticleJournal of psychiatric research2026
Parvalbumin and anxiety across development in female offspring of the MAM neurodevelopmental model of schizophrenia.
Article in Journal of psychiatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Schizophrenia is a neurodevelopmental disorder often accompanied by heightened anxiety. The methylazoxymethanol acetate (MAM) rodent model has demonstrated that prenatal MAM exposure disrupts neurodevelopment and leads to schizophrenia-like deficits, including increased anxiety-like behaviors. While previous research has focused primarily on male subjects, this study investigates anxiety-like behaviors and parvalbumin (PV) interneuron and perineuronal net (PNN) expression in the basolateral amygdala (BLA), thalamic reticular nucleus (TRN), and ventral hippocampus (vHIP) in female MAM rats across postnatal development (PD31-PD75). We found that female MAM rats exhibited increased anxiety-like behaviors in adulthood (PD75), as evidenced by reduced time spent and entries in the open arms of the elevated plus maze and increased center exploration in the open field test. At PD31, an increase in the open arms time and margin exploration was observed in female MAM rats. Interestingly, a baseline hyperlocomotion was observed at PD31 and PD51 in the MAM condition. The TRN also showed reduced PNN density at PD31 and PV density at PD51 which indicates a possible deficit in inhibitory control. Interestingly, in contrast to prior work in males, the BLA did not show alterations in PV or PNN densities that would contribute to increased anxiety, suggesting a different mechanism of anxiety regulation in females compared to males. These findings highlight sex-specific neurodevelopmental alterations following prenatal MAM exposure, emphasizing the need for further research on female models of schizophrenia. Understanding these differences may improve targeted therapeutic strategies for anxiety and psychosis risk in schizophrenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.